- Company announces £100,000 donation to local NHS Trust -
STAINES-UPON-THAMES, United Kingdom, 27 October 2016 -- Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, has announced that it will be opening its new Global Corporate headquarters in Staines-upon-Thames outside London.
The creation of this new Corporate Headquarters in the UK reflects the company's global focus and, in its first phase, will involve the creation of new positions and the movement of key roles from other jurisdictions to locate approximately 45 new jobs in Staines-upon-Thames. The new offices will house the company's corporate strategy functions under Gary Phillips, M.D., Executive Vice President and Chief Strategy Officer.
Commenting, Mark Trudeau, President and Chief Executive Officer of Mallinckrodt, said: "Today's announcement confirms the UK's strategic importance to Mallinckrodt as we continue our transition to become a high-growth, global specialty pharmaceutical business. Our work at this site will drive our efforts to build a diversified, global, specialty pharmaceutical company focused on creating shareholder value by improving revenue growth and profitability. Moreover, as someone who has previously lived in the UK, I look forward to spending a significant amount of my time each year in Staines."
Spelthorne MP Kwasi Kwarteng commented: "Mallinckrodt's decision to establish its global headquarters in Staines-upon-Thames proves that the town is very much ‘open for business'. We have the people, skills and resources that international business requires, and it gives me great pleasure to welcome Mallinckrodt to the area. I first met representatives of the company last year when they were looking at this new investment in the UK and I am proud that my suggestion they consider the Staines area has now come to fruition."
To coincide with the announcement and, in a demonstration of Mallinckrodt's commitment to supporting local healthcare providers and the patient community, the company is also announcing the donation of £100,000 to the local Ashford and St. Peter's Hospitals NHS Foundation Trust, the largest provider of acute hospital services in Surrey. The donation will help the Trust to continue to provide a high quality service to more than 380,000 people in the boroughs of Runnymede, Spelthorne, Woking and parts of Elmbridge, Hounslow, Surrey Heath and beyond.
Dr. Paul Crawshaw, Divisional Director for Women and Children's Services and Consultant Neonatologist at Ashford and St Peter's Hospitals NHS Foundation Trust said: "We are delighted that Mallinckrodt has chosen to link with Ashford and St Peter's Hospitals, and in particular with our Neonatal Intensive Care Unit, and wishes to make such a generous donation. This is a significant sum and will make a real difference to a number of projects across the Trust, such as improving and expanding the Neonatal Intensive Care Unit."
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies, as well as nuclear imaging products. Areas of focus include autoimmune and rare diseases; immunotherapy and neonatal respiratory critical care therapies; analgesics and haemostasis products; and central nervous system drugs.
EndsAbout Mallinckrodt plc
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies, as well as nuclear imaging products. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and haemostasis products; and central nervous system drugs. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Nuclear Imaging segment includes nuclear imaging agents. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.
The Henley Group
+44 1491 570 971
Senior Communications Manager
Chief Public Affairs Officer
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO
Daniel J. Speciale, CPA
Director, Investor Relations